Clinical Trial Record

Return to Clinical Trials

Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer


2009-02


2011-12


2011-12


N/A

Study Overview

Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

N/A

  • Pancreatic Tubular Adenocarcinoma
  • OTHER: Observation
  • Gemcitabine1

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2009-07-24  

N/A  

2010-01-12  

2009-07-24  

N/A  

2010-01-13  

2009-07-27  

N/A  

2009-07  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Pancreatic tubular adenocarcinoma

Patients with pancreatic tubular adenocarcinoma

OTHER: Observation

Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Borut Stabuc, MD, PhD

Phone Number: +386 1 522 22 10

Email: borut.stabuc@kclj.si

Study Contact Backup

Name: Lojze Smid, MD

Phone Number:

Email: lojze.smid.jr@mf.uni-lj.si

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
30 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • ECOG performance status 0-2 at the time of inclusion
  • Following R0 or R1 pancreatic tubular adenocarcinoma resection

  • Exclusion Criteria:

  • Pregnancy
  • Serious comorbidity

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • University Medical Centre Ljubljana

  • : ,

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available